Literature DB >> 12881300

Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment.

Helen V Yarovoi1, Dubravka Kufrin, Don E Eslin, Michael A Thornton, Sandra L Haberichter, Qizhen Shi, Hua Zhu, Rodney Camire, Steve S Fakharzadeh, M Anna Kowalska, David A Wilcox, Bruce S Sachais, Robert R Montgomery, Mortimer Poncz.   

Abstract

Activated platelets release their granule content in a concentrated fashion at sites of injury. We examined whether ectopically expressed factor VIII in developing megakaryocytes would be stored in alpha-granules and whether its release from circulating platelets would effectively ameliorate bleeding in a factor VIIInull mice model. Using the proximal glycoprotein 1b alpha promoter to drive expression of a human factor VIII cDNA construct, transgenic lines were established. One line had detectable human factor VIII that colocalizes with von Willebrand factor in platelets. These animals had platelet factor VIII levels equivalent to 3% to 9% plasma levels, although there was no concurrent plasma human factor VIII detectable. When crossed onto a factor VIIInull background, whole blood clotting time was partially corrected, equivalent to a 3% correction level. In a cuticular bleeding time study, these animals also had only a partial correction, but in an FeCl3 carotid artery, thrombosis assay correction was equivalent to a 50% to 100% level. These studies show that factor VIII can be expressed and stored in platelet alpha-granules. Our studies also suggest that platelet-released factor VIII is at least as potent as an equivalent plasma level and perhaps even more potent in an arterial thrombosis model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12881300     DOI: 10.1182/blood-2003-05-1519

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Infusion of mature megakaryocytes into mice yields functional platelets.

Authors:  Rudy Fuentes; Yuhuan Wang; Jessica Hirsch; Cheng Wang; Lubica Rauova; G Scott Worthen; M Anna Kowalska; Mortimer Poncz
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

2.  VWF and FVIII: the origins of a great friendship.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2009-03-26       Impact factor: 22.113

3.  In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A.

Authors:  Dawei Wang; Guowei Zhang; Junjie Gu; Xiaohu Shao; Yuting Dai; Jianfeng Li; Xiaohong Pan; Shuxian Yao; Aining Xu; Ying Jin; Jinyan Huang; Qizhen Shi; Jiang Zhu; Xiaodong Xi; Zhu Chen; Saijuan Chen
Journal:  Haematologica       Date:  2019-07-11       Impact factor: 9.941

Review 4.  Platelet and endothelial expression of clotting factors for the treatment of hemophilia.

Authors:  Robert R Montgomery; Qizhen Shi
Journal:  Thromb Res       Date:  2012-03-14       Impact factor: 3.944

5.  FLI1 level during megakaryopoiesis affects thrombopoiesis and platelet biology.

Authors:  Karen K Vo; Danuta J Jarocha; Randolph B Lyde; Vincent Hayes; Christopher S Thom; Spencer K Sullivan; Deborah L French; Mortimer Poncz
Journal:  Blood       Date:  2017-04-21       Impact factor: 22.113

6.  Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.

Authors:  Masami Niiya; Masayuki Endo; Dezhi Shang; Philip W Zoltick; Nidal E Muvarak; Wenjing Cao; Sheng-Yu Jin; Christopher G Skipwith; David G Motto; Alan W Flake; X Long Zheng
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

Review 7.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

8.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

9.  Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.

Authors:  Mohammad S Abdelgawwad; Wenjing Cao; Liang Zheng; Nicole K Kocher; Lance A Williams; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

10.  Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.

Authors:  Xuefeng Wang; Richard Y Fu; Chong Li; Chun-Yu Chen; Jenni Firrman; Barbara A Konkle; Junping Zhang; Lei Li; Weidong Xiao; Mortimer Poncz; Carol H Miao
Journal:  Blood Adv       Date:  2020-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.